Obio Technology Shanghai Corp (688238.SS) Stock Price

Obio Technology Shanghai Corp Price

CLOSED
6.75
​
Market closed

Revenue has compounded at 29.3% per year over the past 7 years to 267.70 M CNY. Earnings per share have declined at 26.0% per year over the last 2 years. Obio Technology Shanghai Corp's net margin stands at -87.8%, down from 21.3% several years earlier. Analysts set a median price target of 10.40 CNY, implying 54.1% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

Obio Technology Shanghai Corp stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Obio Technology Shanghai Corp business model & stock analysis

Obio Technology Shanghai Corp Ltd provides biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO services. The company offers contract research organization (CRO) services including gene therapy vector development and gene function research for gene therapy basic research, as well as contract research and development production organization (CDMO) services for gene drug R&D, such as pharmaceutical research and clinical sample production. It serves European and American markets and the domestic market with its CRO and CDMO offerings. The firm generates revenue through CRO services like gene therapy vector development and gene function research, and CDMO services including pharmaceutical research and clinical sample production. Its primary clients are companies involved in gene therapy and gene drug development, focusing on the European and American markets and domestic segments. The company's services support the research and development phases of gene therapy and gene drug products. Obio Technology Shanghai Corp Ltd's business model centers on providing specialized research and production services for gene therapy and gene drug development. By offering both CRO and CDMO services, it addresses key needs in the gene therapy industry, particularly in vector development and clinical sample production, targeting pharmaceutical companies and research institutions in Europe, America, and China.

Frequently asked questions about Obio Technology Shanghai Corp

Analysts currently set an average price target of 10.40 CNY for the Obio Technology Shanghai Corp stock (median: 10.40 CNY), implying +54.1 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the Obio Technology Shanghai Corp stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Obio Technology Shanghai Corp to generate revenue of 297.00 M CNY and earnings per share of -0.30 CNY.

Converted at the current exchange rate, the Obio Technology Shanghai Corp share trades at 0.90 EUR (6.75 CNY).

The expected revenue of Obio Technology Shanghai Corp is 297.00 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Obio Technology Shanghai Corp is -194.71 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Obio Technology Shanghai Corp is currently -22.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Obio Technology Shanghai Corp stock.

The price-to-sales ratio (P/S) of Obio Technology Shanghai Corp is currently 14.75. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Obio Technology Shanghai Corp stock.

The Eulerpool Quality Score for Obio Technology Shanghai Corp is 1/10.

The ISIN of Obio Technology Shanghai Corp is CNE1000059N9. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Obio Technology Shanghai Corp is 688238.SS. The ticker symbol is used to trade Obio Technology Shanghai Corp shares on the stock exchange.

Fair ValueTerminal
7.16 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
424,242.31 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website obiosh.com
Country
Currency
CNY
Initial public offering
Mar 22, 2022
ISIN
CNE1000059N9
Market capitalization
4.38 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-22.50
P/Ee 2027
-33.75
P/Ee 2028
—
P/Ee 2029
—
P/Ee 2030
—
P/Se
14.75
EV/EBIT
—
P/B Ratio
3.11
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-15.22 %
Last updated Oct 22, 2026, 4:42 AM

Obio Technology Shanghai Corp Peer Group

Obio Technology Shanghai Corp FIGI

688238:CH · BBG00VYHNK97688238:CG · BBG011C9BBK4688238:C1 · BBG01G92FJ29